Aurobindo Pharma Ltd.
AUROPHARMA
Aurobindo Pharma continues to be one of the world's fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration. Its API business is supported by technologically advanced research and development infrastructure, which develops new products and plays a role in the delivery of products to the market. It has built a strong presence in key therapeutic segments such as Central nervous system (CNS), cardiovascular (CVS), anti-retroviral (ARV), anti-diabetics, gastroenterology and antibiotics. Also, it is building a diversified pipeline in high-margin specialty generic formulations segment.
Shareholding Pattern
| On | Ind. Pro. | Fore. Pro. | FII/FPI | Mutual Funds | Banks | Insurance | Others | Non/Institution |
|---|---|---|---|---|---|---|---|---|
| 2024-09 | 48.75 | 3.07 | 16.59 | 18.53 | 0.07 | 4.66 | 1.87 | 6.46 |
| 2024-06 | 48.73 | 3.07 | 16.73 | 19.17 | 0 | 5.19 | 0.41 | 6.7 |
| 2024-03 | 48.76 | 3.07 | 18.01 | 17.83 | 0 | 5.03 | 0.43 | 6.87 |
| 2023-12 | 48.76 | 3.07 | 20.72 | 14.7 | 0 | 5.53 | 0.37 | 6.85 |
| 2023-09 | 48.76 | 3.07 | 22.45 | 11.27 | 0 | 6.67 | 0.35 | 7.42 |
| 2023-06 | 48.76 | 3.07 | 24.13 | 8.37 | 0 | 7.03 | 0.33 | 8.31 |
| 2023-03 | 48.76 | 3.07 | 23.02 | 7.64 | 0 | 7.2 | 0.25 | 10.05 |
| 2022-12 | 48.76 | 3.07 | 22.31 | 7.5 | 0 | 7.15 | 0.25 | 10.96 |
| 2022-09 | 48.76 | 3.07 | 21.41 | 8.96 | 0.01 | 7.26 | 0.33 | 10.2 |
Results
| On | Income from Inv. | Int. on Bank Bal. | Int. on Advances | Other Int. | Interest Earned | Interest Exp. | Net Interest Income | Expenditure | Operating Income | Other Income | Prov. & Contingencies | PBT | Tax | PAT | Net Profit | Consolidated Net Profit | Adjusted EPS(Rs.) | Gross NPA | Gross NPA(%) | Net NPA | Net NPA(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09 | 0 | 0 | 0 | 0 | 7796.07 | 112.7 | 7683.37 | 6229.93 | 1702.14 | 136 | 0 | 1207.16 | 390.51 | 816.65 | 816.65 | 817.38 | 14.07 | 0 | 0% | 0 | 0% |
| 2024-06 | 0 | 0 | 0 | 0 | 7567.02 | 111.04 | 7455.98 | 5947.45 | 1840.5 | 220.93 | 0 | 1325.28 | 405.67 | 919.61 | 919.61 | 919.22 | 15.69 | 0 | 0% | 0 | 0% |
| 2024-03 | 0 | 0 | 0 | 0 | 7580.15 | 89.43 | 7490.72 | 5907.34 | 1808.43 | 135.62 | 0 | 1242.56 | 322.55 | 920.01 | 920.01 | 908.75 | 15.51 | 0 | 0% | 0 | 0% |
| 2023-12 | 0 | 0 | 0 | 0 | 7351.78 | 75.55 | 7276.23 | 5750.47 | 1763.83 | 162.52 | 0 | 1265.01 | 322.45 | 942.56 | 942.56 | 936.29 | 15.98 | 0 | 0% | 0 | 0% |
| 2023-09 | 0 | 0 | 0 | 0 | 7219.42 | 68.18 | 7151.24 | 5845.98 | 1560.42 | 186.98 | 0 | 1074.74 | 323.7 | 751.04 | 751.04 | 757.18 | 12.92 | 0 | 0% | 0 | 0% |
| 2023-06 | 0 | 0 | 0 | 0 | 6850.52 | 56.55 | 6793.97 | 5699.15 | 1267.7 | 116.33 | 0 | 814.84 | 242.32 | 572.52 | 572.52 | 570.75 | 9.74 | 0 | 0% | 0 | 0% |
| 2023-03 | 0 | 0 | 0 | 0 | 6472.96 | 55.6 | 6417.36 | 5470.78 | 1137.09 | 134.91 | 0 | 735.92 | 224.15 | 511.77 | 511.77 | 506.27 | 8.64 | 0 | 0% | 0 | 0% |
| 2022-12 | 0 | 0 | 0 | 0 | 6407.13 | 44.96 | 6362.17 | 5452.72 | 1047.06 | 92.65 | 0 | 680.7 | 189.1 | 491.6 | 491.6 | 491.26 | 8.38 | 0 | 0% | 0 | 0% |
| 2022-09 | 0 | 0 | 0 | 0 | 5739.37 | 25.29 | 5714.08 | 4948.58 | 847.98 | 57.19 | 0 | 524.59 | 112.99 | 411.6 | 411.6 | 409.45 | 6.99 | 0 | 0% | 0 | 0% |
| 2022-06 | 0 | 0 | 0 | 0 | 6235.92 | 14.63 | 6221.29 | 5299.44 | 977.1 | 40.62 | 0 | 682.96 | 158.61 | 524.35 | 524.35 | 520.54 | 8.88 | 0 | 0% | 0 | 0% |